CurrentBlue Cross Blue Shield - MassachusettsPolicy 248

Extracorporeal Photopheresis (ECP) — Medical Necessity and Prior Authorization

Clinical policy governing medical necessity and prior authorization for extracorporeal photopheresis for commercial members of Blue Cross Blue Shield - Massachusetts; defines covered and investigational indications and inpatient/outpatient authorization rules.

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicyExtracorporeal Photopheresis (ECP) — Medical Necessity and Prior Authorization

Policy CodePolicy 248

Change TypeNo material changes

Effective Date

Next Review Date

Key ActionObtain precertification/preauthorization for all inpatient ECP services; document refractory status to standard therapies when requesting ECP for GVHD or CTCL.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

36522Primary CPT code

4Covered indications

multipleInvestigational indications

RequiredInpatient auth

Not requiredOutpatient prior auth (Commercial)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Extracorporeal Photopheresis (ECP)

Medically Necessary Indications

ECP is considered MEDICALLY NECESSARY for the following conditions:

Medically necessary indications: Cardiac allograft rejection, including acute rejection, that is either recurrent or that is refractory to standard immunosuppressive drug treatmentrecurrent or refractory to standard immunosuppression

From policy medically necessary list

Medically necessary indications: Acute graft-versus-host disease or chronic graft-versus-host disease that is refractory to medical therapyrefractory to medical therapy

From policy medically necessary list

Medically necessary indications: Late-stage (III/IV) cutaneous T-cell lymphomaStage III or IV

From policy medically necessary list

Medically necessary indications: Early stage (I/II) cutaneous T-cell lymphoma that is progressive and refractory to established nonsystemic therapiesprogressive and refractory to nonsystemic therapies

From policy medically necessary list

Investigational / Not Medically Necessary Indications

ECP is considered INVESTIGATIONAL for the following conditions:

Investigational list: Treatment or prevention of rejection in solid-organ transplantation except for rejection that is recurrent or refractory to standard immunosuppressive drug treatmentnot recurrent/refractory

Investigational per policy

Investigational list: Acute graft-versus-host disease or chronic graft-versus-host disease that is previously untreated or is responding to established therapiespreviously untreated or responding

Investigational per policy

Investigational list: Cutaneous or visceral manifestations of autoimmune diseases (including but not limited to scleroderma, systemic lupus erythematosus, rheumatoid arthritis, pemphigus, psoriasis, multiple sclerosis, diabetes, autoimmune bullous disorders, severe atopic dermatitis, Crohn disease)

Coverage by indication

Coverage stance varies by indication; covered when criteria for each indication are met as below.

Graft-Versus-Host Disease (GVHD): ECP is considered effective for acute or chronic GVHD refractory to medical treatment; evidence shows ECP reduces incidence and treats GVHD unresponsive to standard therapy and can allow reduction or discontinuation of corticosteroids and other immunosuppressants.evidence of refractory disease to standard therapy

Supported by systematic reviews, randomized study, and retrospective studies

Cutaneous T-Cell Lymphoma (CTCL): ECP is considered effective for advanced-stage (stage III or IV) CTCL and is an option for refractory or progressive early-stage (stage I or II) CTCL after failure of nonsystemic therapies; evidence shows favorable responses and survival benefit in a proportion of patients.documented stage and prior therapies

Supported by systematic reviews and case series indicating improved net health outcome.

Kidney Transplant Recurrent Graft Rejection:

Extracorporeal photopheresis (ECP) is investigational for all other indications not specifically listed as medically necessary. This policy designates the listed medically necessary uses explicitly (cardiac allograft rejection that is recurrent or refractory, refractory acute or chronic graft‑versus‑host disease, late‑stage [III/IV] cutaneous T‑cell lymphoma, and progressive/refractory early‑stage [I/II] CTCL); any indication outside of those is considered investigational and not covered under this policy.

Certain indications are excluded from coverage because the evidence is insufficient to determine a net health benefit. Specifically, use of ECP for recurrent kidney transplant graft rejection is unsupported by adequate randomized data and therefore considered investigational, and use of ECP for a range of autoimmune diseases (examples include scleroderma, systemic lupus erythematosus, rheumatoid arthritis, pemphigus, psoriasis, multiple sclerosis, diabetes, autoimmune bullous disorders, severe atopic dermatitis, and Crohn disease) is similarly not supported by sufficient, robust literature to justify coverage.

Use of ECP for the treatment or prevention of rejection in solid‑organ transplantation is not considered medically necessary except when the rejection is documented as recurrent or refractory to standard immunosuppressive drug treatment. In other words, ECP is excluded for routine or first‑line management of solid‑organ transplant rejection and is limited to the specific recurrent/refractory transplant rejection scenario described in the medically necessary indications.

Use of ECP for recurrent kidney transplant graft rejection and for multiple listed autoimmune diseases is considered unsupported by sufficient evidence to determine a meaningful improvement in net health outcome. These indications should be treated as investigational/not medically necessary in the absence of stronger trial data or participation in a clinical study.

Coding — Procedure and Diagnosis Codes

Covered CPT CodesCPTCovered

36522

Photopheresis, extracorporeal

Listed ICD-10 Codes (transplant complications/rejection)ICD-10

D89.812	Chronic graft-versus-host disease
D89.813	Acute on chronic graft-versus-host disease / GVHD unspecified
T86.00	Unspecified complication of bone marrow transplant
T86.01	Bone marrow transplant rejection
T86.02	Bone marrow transplant failure
T86.03	Bone marrow transplant infection
T86.09	Other complications of bone marrow transplant
T86.21	Heart transplant rejection
T86.31	Heart-lung transplant rejection
T86.5	Complications of stem cell transplant

GVHD: acute vs chronic timing

Acute GVHD timingOccurs within the first 100 days after infusion of allogeneic cells

Chronic GVHD timingDevelops sometime after 100 days following allogeneic cell infusion

Severity grading (acute)Acute GVHD commonly graded I–IV (grades III–IV indicate severe to life‑threatening disease)

Provider Actions, Prior Authorization, and Documentation

Prior Authorization

Inpatient Prior Authorization Required

For services described in this policy, precertification/preauthorization is REQUIRED for all products if the procedure is performed inpatient. Failure to obtain required inpatient precertification/authorization may result in denial of payment.

Precertification/preauthorization required for all inpatient ECP procedures across products.
Denial risk if inpatient authorization is not obtained prior to service.

Note

Kidney Transplant — Limited Evidence

The evidence for use of extracorporeal photopheresis (ECP) in kidney transplant recipients with recurrent graft rejection is limited. Current literature (small prospective study and case reports) is insufficient to determine that ECP improves net health outcome for kidney transplant rejection. Document clinical rationale and supporting evidence when requesting coverage in this population.

ECP for kidney transplant rejection is considered investigational/insufficient — provide detailed clinical documentation if requesting authorization.

Line of Therapy / Treatment Setting

salvage

CTCL late-stage: Late-stage (III/IV) CTCL is coveredStage III or IV

Policy indicates ECP is medically necessary for late-stage CTCL

CTCL early-stage progressive refractory: Early-stage (I/II) CTCL covered only if progressive and refractory to established nonsystemic therapiesprogressive and refractory to nonsystemic therapies

Policy limitation for early-stage disease

salvage

Advanced CTCL:

Covered Regimens and Treatment Settings

Indication	Regimen	Coverage status	Supporting rationale / criteria
Advanced-stage (stage III or IV) cutaneous T‑cell lymphoma (CTCL)	Extracorporeal photopheresis (ECP)	Covered	Systematic review and multiple small case series demonstrating favorable responses and increased survival in a proportion of patients; evidence sufficient to show improved net health outcome

Indication	Regimen	Coverage status	Supporting rationale / criteria
Refractory or progressive early‑stage (stage I or II) CTCL after failure of established nonsystemic therapies	Extracorporeal photopheresis (ECP) — considered an option	Covered	Systematic review evidence plus consideration of unfavorable prognosis for progressing early‑stage disease, favorable response rates to ECP, and relatively low adverse events compared with other systemic therapies; evidence sufficient to support ECP as an option

Background on Extracorporeal Photopheresis

Extracorporeal photopheresis (ECP) is a leukapheresis‑based immunomodulatory procedure performed in three core steps: collection of the patient’s blood and separation of a leukocyte‑rich fraction by leukapheresis; exposure of the collected leukocytes to the photosensitizing agent 8‑methoxypsoralen (8‑MOP); followed by irradiation with ultraviolet A (UVA) light and reinfusion of the treated cells into the patient. The intended mechanism is immunomodulation via reintroduction of photochemically altered lymphocytes that can induce immune tolerance or modify pathologic immune responses.

Definitions and Key Terms

Extracorporeal photopheresis (ECP) — definition and procedure

DefinitionExtracorporeal photopheresis (ECP) is a leukapheresis‑based immunomodulatory procedure that separates leukocyte‑rich blood, treats the lymphocyte fraction with 8‑methoxypsoralen and UVA, then reinfuses the treated lymphocytes

Step 1Collect patient blood and separate the leukocyte‑rich (buffy coat) fraction via centrifugation

Step 2Add photosensitizer 8‑methoxypsoralen to the lymphocyte fraction and expose to ultraviolet‑A light (320–400 nm) at a dose of 1–2 J/cm2

Step 3Reinfuse the light‑sensitized lymphocytes back into the patient

Refractory rejection

DefinitionRefractory rejection: rejection that fails to respond adequately to a standard regimen of immunosuppressive therapy

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicyExtracorporeal Photopheresis (ECP) — Medical Necessity and Prior Authorization

Policy CodePolicy 248

Change TypeNo material changes

Effective Date

Next Review Date

Key ActionObtain precertification/preauthorization for all inpatient ECP services; document refractory status to standard therapies when requesting ECP for GVHD or CTCL.

SourceLink

On This Page

any listed autoimmune condition

Investigational per policy

Investigational list: Early stage (I/II) cutaneous T-cell lymphoma that is previously untreated or is responding to established nonsystemic therapiespreviously untreated or responding

Investigational per policy

Evidence is insufficient to determine that ECP improves net health outcome for kidney transplant recipients with recurrent graft rejection; randomized trials are needed.

Small prospective study and case reports available.

Autoimmune Diseases: ECP for autoimmune diseases (eg, cutaneous or visceral manifestations such as scleroderma, SLE, RA, pemphigus, psoriasis, MS, diabetes, autoimmune bullous disorders, severe atopic dermatitis, Crohn disease) has limited and inconsistent evidence; insufficient to determine improvement in net health outcome.none specified

Evidence consists of isolated RCTs, small studies, and case reports.

Randomized controlled trial evidence is lacking; histologic confirmation of response is needed in studies.

Note

CMS National Coverage Determination Referenced

CMS National Coverage Determination (NCD 110.4) for extracorporeal photopheresis is referenced and may inform coverage decisions and prior authorization practices. Review and cite the CMS NCD when applicable to Medicare members or when aligning policy decisions with federal guidance.

CMS NCD link: https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=113
Payers may use CMS NCD and other guideline documents to inform prior authorization requirements.

Billing Rule

Coding and Billing Documentation

Providers must report all services using current industry-standard procedure, revenue, and diagnosis codes, and include applicable modifiers. Accurate coding and documentation are required to support medical necessity determinations.

Report services with the most up-to-date CPT/HCPCS and ICD-10 codes and applicable modifiers.
Include procedure/revenue codes and supporting diagnosis codes that reflect refractory or recurrent disease when applicable.

Documentation Required

GVHD Documentation Requirements

When requesting authorization for graft-versus-host disease (GVHD), document that the condition is acute or chronic GVHD and is refractory to medical treatment or recurrent after standard therapy. Include prior therapies tried, clinical course, and any objective measures of treatment failure.

Document prior systemic and topical therapies, duration of treatment, and objective evidence of refractory disease.
Include rationale for ECP, expected benefit, and plan for steroid or immunosuppressant tapering if response occurs.

Documentation Required

CTCL Documentation Requirements

For cutaneous T-cell lymphoma (CTCL) requests, document disease stage (early I/II or advanced III/IV), prior therapies, and whether disease is progressive or refractory to established nonsystemic or systemic treatments as applicable. For early-stage CTCL, show progression on or refractoriness to nonsystemic therapies before considering ECP.

Include staging information (TNMB/stage), prior topical or systemic therapies and responses, and evidence of progression or refractory disease.
For advanced-stage CTCL, include prior systemic therapy history and clinical response details.

Note

Guideline Citations

Clinical practice guidelines and consensus recommendations (for example, NCCN guidelines for primary cutaneous lymphomas and hematopoietic cell transplantation, and professional society guidance on GVHD management) are cited in this policy and may inform coverage and documentation expectations. Providers should reference relevant guideline recommendations in authorization requests.

NCCN guideline references may be used to support medical necessity for CTCL and transplantation-related indications.
Consensus recommendations for GVHD treatment can support ECP use when disease is steroid-refractory or refractory to standard therapies.

ECP indicated for advanced-stage (III/IV) CTCL; evidence shows improvement in net health outcome for some patients.

documented stage III/IV

salvage

Early-stage refractory CTCL: ECP is an option for refractory or progressive early-stage (I/II) CTCL after failure of nonsystemic therapies.evidence of progression/refractoriness to nonsystemic therapies

Context of useApplied to solid‑organ or cardiac allograft rejection that is recurrent or refractory to standard immunosuppression

Coverage implicationECP may be considered medically necessary for recurrent or refractory cardiac allograft rejection

GVHD refractory to medical treatment

DefinitionGVHD refractory to medical treatment: acute or chronic graft‑versus‑host disease that does not adequately respond to standard medical therapy (eg, corticosteroids, other systemic immunosuppressants)

Clinical consequenceECP has been shown to reduce incidence of GVHD unresponsive to standard therapy and may permit reduction/discontinuation of corticosteroids/immunosuppressants

Evidence basisSupported by systematic reviews, randomized and retrospective studies, and case series showing improved net health outcome

CTCL: advanced‑stage (Stage III or IV) definition

DefinitionAdvanced‑stage CTCL (stage III or IV): cutaneous T‑cell lymphoma involving advanced skin disease and/or nodal or visceral involvement consistent with stage III or IV

Coverage stanceECP is considered medically necessary for advanced‑stage (stage III or IV) CTCL

Alternative useECP is an option for refractory or progressive early‑stage (I/II) CTCL after failure of nonsystemic therapies, but stage III/IV denotes advanced disease for primary coverage